nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2

IntroductionThe phase II ABOUND.PS2 study (NCT02289456) assessed safety/tolerability of a first-line modified nab-paclitaxel/carboplatin regimen for patients with advanced non-small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2.MethodsChemotherapy-n...

Full description

Bibliographic Details
Main Authors: Ajeet Gajra, Nagla Abdel Karim, Deborah A. Mulford, Liza Cosca Villaruz, Marc Ryan Matrana, Haythem Y. Ali, Edgardo S. Santos, Tymara Berry, Teng Jin Ong, Alexandra Sanford, Katayoun Amiri, David R. Spigel
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-07-01
Series:Frontiers in Oncology
Subjects:
chemotherapy
maintenance therapy
nab-paclitaxel
non-small cell lung cancer
poor performance status
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2018.00253/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2018.00253/full

Similar Items